A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Alzheimer's Disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
-
Yale University, New Haven, Connecticut, United States, 06511
Spaulding Clinical Research, West Bend, Wisconsin, United States, 53095
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to 80 Years
ALL
No
Allyx Therapeutics,
Adam Mecca, MD, PhD, STUDY_DIRECTOR, Yale University
Stephanie Post, MD, PRINCIPAL_INVESTIGATOR, Spaulding Clinical Research (Stage 1)
Adam Mecca, MD, PhD, PRINCIPAL_INVESTIGATOR, Yale University (Stage 2)
2025-07-15